OUR PIPELINE

Our pipeline is initially focused on three core therapeutic areas - the renal, central nervous and ocular systems - with our drug design capability and proprietary drug delivery platform providing the potential to address a much broader range of indications.
An image of a middle aged man holding a toddler up in the air. The toddler's nose and his nose are touching and they are both smiling. They are in a forest and the sun is shining through the trees behind them.

ORGAN
PROGRAM & TARGET
STATUS
PREVALENCE
An icon of two white kidneys connected by a large blood vessel.
PYC-003
PKD1
View program
Autosomal Dominant Polycystic Kidney Disease
Clinical trials (Phase 1b)
Discovery Pre-clinical IND-enabling Clinical trials Marketed
1 in 1,000
A white icon of the brain from a birds eye view.
PYC-002
SHANK3
View program
Phelan-McDermid Syndrome
IND-enabling
Discovery Pre-clinical IND-enabling Clinical trials Marketed
1 in 7,300
An icon of a white eye.
PYC-001
OPA1
View program
Autosomal Dominant Optic Atrophy
Clinical trials (Phase 1/2)
Discovery Pre-clinical IND-enabling Clinical trials Marketed
1 in 35,000
An icon of a white eye.
VP-001*
PRPF31
View program
Retinitis Pigmentosa type 11
Clinical trials (Phase 1/2)
Discovery Pre-clinical IND-enabling Clinical trials Marketed
1 in 100,000
PYC Therapeutics logo (white version)
Not disclosed
Haploinsufficiencies of major unmet need
Discovery programs
Discovery
Discovery Pre-clinical IND-enabling Clinical trials Marketed
*PYC owns 97.1% of VP-001, with the remaining 2.9% held by the Lions Eye Institute, Australia, and wholly owns all other pipeline programs